New agents for treatment of systemic fungal infections

Bibliography

• WINGARD J: Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy. Clin. Infect. Dis. (1994) 19:S49–S53.
   Google Scholar
• ANAISSIE E, BODEY GP, KANTARJIAN H, et al.: New spectrum of fungal infections in patients with cancer. Rev. Infect. Dis. (1989) 11:369–378.
   PubMedGoogle Scholar
• •Informative on emerging fungal pathogens.
   Google Scholar
• PATEL R, PORTELA D, BADLEY AD, et al.: Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation (1996) 62:926–934.
   PubMed Web of Science ®Google Scholar
• HIEMENZ JW, WALSH TJ: Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. (1996) 22:S133–S144.
   Google Scholar
• KORTING HC, SCHAFER-KORTING M, ZIENICKE H, GEORGII A, OLLERT MW: Treatment of tinea unguium with medium and high doses of uhrarnicrosize griseo-fulvin compared with that with itraconazole. Antimi-crob. Agents Chemother. (1993) 37:2064–2068.
   PubMed Web of Science ®Google Scholar
• HIEMENZ JW, WALSH TJ: Lipid formulations of amphotericin B. J. Liposome Res. (1998) 8:443–467.
   Web of Science ®Google Scholar
• ••Review article on currently available lipid-basedamphotericin B formulations.
   Google Scholar
• TERRELL CL, HUGHES CE: Antifungal agents used for deep-seated mycotic infections. Mayo. Clin. Proc. (1992) 67: 69–91.
   Google Scholar
• WALSH TJ, MELCHER GP, RINALDI MG, et al.: Tricho-sporon beigelii, an emerging pathogen resistant to amphotericin B. J. Clin. Microbiol. (1990) 28: 1616-1622.
   Google Scholar
• GUEHO E, SMITH MT, DE HOOG GS, et al.: Contributions to a revision of the genus Tricbosporon. Antonie van Leeuwenhoek (1992) 61:289–316.
   PubMed Web of Science ®Google Scholar
• SUTTON DA, SANCHE SE, REVANKAR SG, FOTHERGILLAW, RINALDI MG: In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with head-to-head comparison to voriconazole. J. Clin. Microbiol. (1999) 37:2343–2345.
   PubMed Web of Science ®Google Scholar
• WALSH M, WHITE L, ATKINSON K, ENNO A: Fungal Pseudallescberiaboydii lung infiltrates unresponsive to amphotericin B in leukaemic patients. Aust. NZ J. Med. (1992) 22: 265–268.
   Google Scholar
• FRANCIS P, WALSH TJ: Approaches to management offungal infections in cancer patients. Oncology (1992) 6: 133–144.
   Google Scholar
• ARIKAN S, LOZANO-CHIU M, PAETZNICK V, NANGIA S, REX JH: Microdilution susceptibility testing of amphotericin B, itraconazole and voriconazole against clinical isolates of Aspergillus and Fusarium species. J. Clin. Microbiol. (1999) 37:3946–3951.
   PubMed Web of Science ®Google Scholar
• KARYOTAKIS NC, ANAISSIE EJ, HACHEM R, DIGNANI MC, SAMONIS G: Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice. J. Infect. Dis. (1993) 168:1311–1313.
   PubMed Web of Science ®Google Scholar
• •Evidence of limited activity of amphotericin B against Candida krusei.
   Google Scholar
• KARYOTAKIS NC, ANAISSIE EJ: Efficacy of escalating doses of liposomal amphotericin B (ArnBisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic mice. Antimi-crob. Agents Chemother. (1994) 38:2660–2662.
   PubMed Web of Science ®Google Scholar
• SABRA R, BRANCH RA: Mechanisms of amphotericin B-induced decrease in glomerular filtration rate in rats. Antimicrob. Agents Chemother. (1991)35:2509-2514.
   Google Scholar
• MEYER RD: Current role of therapy with amphotericin B. Clin. Infect. Dis. (1992) 14 (Suppl. 1):S154–S160.
   Google Scholar
• JANKNEGT R, DE MARIE S, BAKKER-WOUDENBERG IA, CROMMELIN DJ: Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin. Pharmacokin. (1992) 23:279–291.
   PubMed Web of Science ®Google Scholar
• ANAISSIE EJ, MATTIUZZI GN, MILLER CB, et al.: Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion. Antimicrob. Agents Chemother. (1998) 42:606–611.
   PubMed Web of Science ®Google Scholar
• OLDFIELD EC, 3rd, GARST PD, HOSTETTLER C, WHITE M, SAMUELSON D: Randomized, double-blind trial of 1-versus 4-hour amphotericin B infusion durations. Antimicrob. Agents Chemother. (1990) 34: 1402–1406.
   Google Scholar
• STORM G, VAN ETTEN E: Biopharmaceutical aspects of lipid formulations of amphotericin B. Eur. J. Clin. Micro biol. Infect. Dis. (1997) 16:64–73.
   PubMed Web of Science ®Google Scholar
• SHEEHAN DJ, HITCHCOCK CA, SIBLEY CM: Current and emerging azole antifungal agents. Clin. Micro biol. Rev. (1999) 12: 40–79.
   Google Scholar
• GHANNOUM MA, REX JH, GALGIANI JN: Susceptibility testing of fungi: Current status of the correlation of in vitro data with clinical outcome. J. Clin. Microbiol. (1996) 34: 489–495.
   Google Scholar
• •Informative on significance of in vitro susceptibility testing in estimation of clinical response.
   Google Scholar
• ARIKAN S, AKOVA M, HAYRAN M, et al.: Correlation of in vitro fluconazole susceptibility with clinical outcome for severely ill patients with oropharyngeal candidia-sis. Clin. Infect. Dis. (1998)26:903-908.
   Google Scholar
• WONG-BERINGER A, JACOBS RA, GUGLIELMO BJ: Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. (1998) 27:603–618.
   PubMed Web of Science ®Google Scholar
• ••Review article on clinical use of lipid-based amphotericin Bpreparations.
   Google Scholar
• LEENDERS ACAP, DE MARIE S: The use of lipid formula- tions of amphotericin B for systemic fungal infections. Leukemia (1996) 10:1570–1575.
   PubMed Web of Science ®Google Scholar
• HIEMENZ JW, LISTER J, ANAISSIE E: Emergency useamphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: historical control comparison with amphotericin B. Blood (1995) 86\(Suppl. 1):849a.
   Google Scholar
• JANOFF AS, PERKINS WR, SALETON SL, SWENSON CE: Amphotericin B lipid complex (ABLC): a molecular rationale for the attenuation of amphotericin B-related toxicities. J. Liposome Res. (1993)3:451-472.
   Google Scholar
• OLSEN SJ, SWERDEL MR, BLUE B, CLARK JM, BONNER DP: Tissue distribution of amphotericin B lipid complex in laboratory animals. J. Pharmacol. (1991) 43:831–835.
   Google Scholar
• LISTER J: Amphotericin B lipid complex (Abeket) in the treatment of invasive mycoses: the North American experience. Eur. J. Haematol. (1996) 56:18S–23S.
   Google Scholar
• GARNACHO-MONTERO J, ORTIZ-LEYBA C, GARMENDIAJLG, JIMENEZ FJJ: Life-threatening adverse event after amphoterin B lipid complex treatment in a patient treated previously with amphoterin B deoxycholate. Clin. Infect. Dis. (1998) 26:1016.
   PubMed Web of Science ®Google Scholar
• WINGARD JR: Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipi-ents with life-threatening systemic mycoses. Bone Marrow Transplant. (1997) 19:343–347.
   PubMed Web of Science ®Google Scholar
• GUO LSS, FIELDING RM, LASIC DD: Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discs. Int. J. Pharm. (1991)75:45-54.
   Google Scholar
• OPPENHEIM BA, HERBRECHT R, KUSNE S: The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin. Infect. Dis. (1995) 21:1145–1153.
   PubMed Web of Science ®Google Scholar
• WHITE MH, BOWDEN RA, SANDLER E, et al.: Amphotericin B colloidal dispersion vs. amphotericin B in the empiric treatment of febrile neutropenic patients. Blood (1996) 88\(Suppl. 1):302a.
   PubMed Web of Science ®Google Scholar
• PATEL R: Amphotericin B colloidal dispersion. Exp. Opin. Pharmacother. (2000) 1(3):475–488.
   PubMedGoogle Scholar
• WORKING PK: Amphotericin B colloidal dispersion Pre-clinical review. Chemotherapy (1999) 45\(Suppl. 1):15–26.
   PubMed Web of Science ®Google Scholar
• WHITE MH, ANAISSIE EJ, KUSNE S, et al.: Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin. Infect. Dis. (1997) 24:635–642.
   PubMed Web of Science ®Google Scholar
• VALERO G, GRAYBILL JR: Successful treatment of Cryptococcal meningitis with amphotericin B colloidal dispersion: report of four cases. Antimicrob. Agents Chemother. (1995) 39:2588–2590.
   PubMed Web of Science ®Google Scholar
• WHITE MH, BOWDEN RA, SANDLER ES, et al.: Random-ized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin. Infect. Dis. (1998) 27: 296–302.
   Google Scholar
• JOHNSON JR, KANGAS PJ, WEST M: Serious adverse event after unrecognized substitution of one amphotericin B lipid preparation for another. Clin. Infect. Dis. (1998) 27:1342–1343.
   PubMed Web of Science ®Google Scholar
• •Emphasises the different adverse drug reaction profile for different lipid-based amphotericin B formulations.
   Google Scholar
• ADLER-MOORE JP, PROFFITT RT: Development, charac-terization, efficacy and mode of action of ArnBisome, a unilamellar liposomal formulation of amphotericin B. J. Liposome Res. (1993) 3:429–450.
   Google Scholar
• LEE JW, AMANTEA MA, FRANCIS PA: Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob. Agents Chemother. (1994) 38: 713–718.
   Google Scholar
• PROFFITT RT, SATORIUS A, CHIANG SM, SULLIVAN L, ADLER-MOORE JP: Pharmacology and toxicology of a liposomal formulation of amphotericin B (ArnBisome) in rodents. J. Antimicrob. Chemother. (1991) 28(Suppl. B):49–61.
   PubMedGoogle Scholar
• GROLL A, GIRI N, GONZALEZ C, et al Penetration of lipid formulations of amphotericin B into cerebrospinal fluid and brain tissue. 37th Intersczence Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract A–90.
   Google Scholar
• FRANCIS P, LEE JW, HOFFMAN A, et al.: Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocy-topenic rabbits: the potential role of bronchoalveolar lavage n-marmitol and galactomarman as markers of infection. J. Infect. Dis. (1994) 169:356–368.
   PubMed Web of Science ®Google Scholar
• ELLIS M, SPENCE D, DE PAUW B, et al.: An EORTC interna-tional multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive as pergillosis. Clin. Infect. Dis. (1998) 27:1406–1412.
   PubMed Web of Science ®Google Scholar
• WALSH TJ, YELDANDI V, MCEVOY M, et al.: Safety, tolerance and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob. Agents Chemother. (1998) 42:2391–2398.
   PubMed Web of Science ®Google Scholar
• •Clinical use of liposomal amphotericin B in febrile neutro-penic patients.
   Google Scholar
• TOLLEMAR J, RINGDEN 0, ANDERSSON S, et al.: Random-ized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant. (1993) 12:577–582.
   PubMed Web of Science ®Google Scholar
• LAING RBS, MILNE LJR, LEEN CLS, MALCOM GP, STEERS AJ: Anaphylactic reactions to liposomal amphotericin. Lancet (1994) 344:682.
   PubMed Web of Science ®Google Scholar
• TORRE I, LOPEZ-HERCE J, VAZQUEZ P: Anaphylacticreaction to liposomal amphotericin B in children. Ann. Pharmacother. (1996) 30:1037–1038.
   PubMed Web of Science ®Google Scholar
• AYESTARAN A, LOPEZ RM, MONTORO JB, et al.: Pharma-cokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia. Antimicrob. Agents Chemother. (1996) 40:609–612.
   PubMed Web of Science ®Google Scholar
• CAILLOT D, CHAVANET P, CASANOVAS 0 et al.: Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B. Eur. J. Clin. Micro biol. Infect. Dis. (1992) 11:722–725.
   PubMed Web of Science ®Google Scholar
• SORKINE P, NAGAR H, WEINBROUM A, et al.: Administra-tion of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients. Crit. Care Med. (1996) 24:1311–1315.
   PubMed Web of Science ®Google Scholar
• SCHOFFSKI P, FREUND M, WUNDER R, et al.: Safety andtoxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study. Br. Med. J. (1998) 317:379–384.
   PubMed Web of Science ®Google Scholar
• TORRE D, BANFI G, TAMBINI R, et al.: A retrospective study on the efficacy and safety of amphotericin B in a lipid emulsion for the treatment of Cryptococcal meningitis in AIDS patients. J. Infect. (1998) 37:36–38.
   PubMed Web of Science ®Google Scholar
• BARQUIST E, FEIN E, SHADICK D, JOHNSON J, CLARK J, SHATZ D: A randomized prospective trial of amphotericin B lipid emulsion versus dextrose colloidal solution in critically ill patients. J. Trauma (1999) 47:336–340.
   PubMed Web of Science ®Google Scholar
• MOREAU P, MILPIED N, FAYETTE N, RAME JF, HAROUS-SEAU JL: Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J. Antimicrob. Chemother. (1992) 30:535–541.
   PubMed Web of Science ®Google Scholar
• NUCCI M, LOUREIRO M, SILVEIRA F, et al.: Comparison ofthe toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients. Antimicrob. Agents Chemother. (1999) 43:1445–1448.
   PubMed Web of Science ®Google Scholar
• ANDERSON RP, CLARK DA: Amphotericin B toxicity reduced by administration in fat emulsion. Ann. Pharmacother. (1995) 29:496–500.
   PubMed Web of Science ®Google Scholar
• GALES MA, GALES BJ, ALFORD KM: Acute renal failurewith amphotericin B in lipid emulsion. Ann. Pharmaco-ther. (1996) 30:1036.
   PubMed Web of Science ®Google Scholar
• ERICSSON O, HALLMEN A-C, WIKSTROM I: Amphotericin B is incompatible with lipid emulsions. Ann. Pharmacother. (1996) 30:298.
   PubMedGoogle Scholar
• TRISSEL LA: Amphotericin B does not mix with fat emulsion. Am. J. Health-System Pharm. (1995) 52:1463–1464.
   PubMed Web of Science ®Google Scholar
• WALKER S, TAILOR SAN, LEE M, et al.: Amphotericin B inlipid emulsions: Stability, compatibility and in vitro antifungal activity. Antimicrob. Agents Chemother. (1998) 42:762–766.
   PubMed Web of Science ®Google Scholar
• OWENS D, FLEMING RA, RESTINO MS, CRUZ JM, HURDDD: Stability of amphotericin B 0.05 and 0.5 mg/ml in 20% fat emulsion. Am. J. Health-System Pharm. (1997) 54:683–686.
   PubMed Web of Science ®Google Scholar
• CLEARY JD: Amphotericin B formulated in a lipid emulsion. Ann. Pharmacother. (1996) 30:409–412.
   PubMed Web of Science ®Google Scholar
• ODDS FC, CHEESMAN SL, ABBOTT AB: Antifungal effectsof fluconazole (UK 49858), a new triazole antifungal, in vitro. J. Antimicrob. Chemother. (1986) 18:473–478.
   PubMed Web of Science ®Google Scholar
• Fromtling RA (Ed.), JR Prous Science Publishers, Barcelona, Spain (1987):81–92.
   Google Scholar
• LYMAN CA, WALSH TJ: Systemically administered antifungal agents. A review of their clinical pharma-cology and therapeutic applications. Drugs (1992) 44:9–35.
   PubMed Web of Science ®Google Scholar
• COMO JA, DISMUKES WE: Oral azole drugs as systemic antifungal therapy. N. Engl. J. Med. (1994) 330:263–272.
   PubMed Web of Science ®Google Scholar
• ANAISSIE EJ, KONTONYIANNIS DP, HULS C, et al.: Safety, plasma concentrations and efficacy of high-dose fluconazole in invasive mold infections. J. Infect. Dis. (1995) 172:599–602.
   PubMed Web of Science ®Google Scholar
• BERRY AJ, RINALDI MG, GRAYBILL JR: Use of high-dosefluconazole as salvage therapy for Cryptococca/ meningitis in patients with AIDS. Antimicrob. Agents Chemother. (1992) 36:690–692.
   PubMed Web of Science ®Google Scholar
• HAUBRICH RH, HAGHIGHAT D, BOZZETTE SA, TILLES J,MCCUTCHAN JA, THE CALIFORNIA COLLABORATIVE TREATMENT GROUP: High-dose fluconazole for treatment of Cryptococcal disease in patients with human inimunodeficiencyvirus infection. J. Infect. Dis. (1994) 170:238–242.
   PubMed Web of Science ®Google Scholar
• MENICHETTI F, FIORIO M, TOSTI A, et al.: High-dosefluconazole therapy for Cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. (1996) 22:838–840.
   PubMed Web of Science ®Google Scholar
• GALGIANI JN: Coccidioidomycosis. West. J. Med. (1993)159:153–171.
   PubMedGoogle Scholar
• WHEAT J, MAWHINNEY S, HAFNER R, et al.: Treatment ofhistoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. Am. J. Med. (1997) 103:223–232.
   PubMed Web of Science ®Google Scholar
• PAPPAS PG, BRADSHER RW, KAUFFMAN CA, et al.: Treatment of blastomycosis with higher doses of fluconazole. Clin. Infect. Dis. (1997) 25:200–205.
   PubMed Web of Science ®Google Scholar
• KAUFFMAN CA, PAPPAS PG, MCKINSEY DS, et al.: Treatment of lymphocutaneous and visceral sporotri-chosis with fluconazole. Clin. Infect. Dis. (1996) 22:46–50.
   PubMed Web of Science ®Google Scholar
• REX JH, PFALLER MA, GALGIANI, JN et al.: Developmentof interpretive breakpoints for antifungal suscepti-bility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itracona-zole and Candida infections. Clin. Infect. Dis. (1997) 24:235–247.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MESSER SA, HOLLIS RJ, et al.: Trends inspecies distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn. Microbiol. Infect. Dis. (1999) 33:217–222.
   PubMed Web of Science ®Google Scholar
• REX JH, RINALDI MG, PFALLER MA: Resistance ofCandida species to fluconazole. Antimicrob. Agents Chemother.(1995) 39: 1–8.
   Google Scholar
• DENNING DW, HANSON LH, PERLMAN AM, STEVENS DA:In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn. Microbiol. Infect. Dis. (1992) 15:21–34.
   PubMed Web of Science ®Google Scholar
• DEBRUYNE D, RYCKELYNCK JP: Clinical pharmacoki-netics of fluconazole. Clin. Pharmacokinet. (1993) 24:10–27.
   PubMed Web of Science ®Google Scholar
• MALIK IA, MOID I, AZIZ Z, KHAN S, SULEMAN M: A randomized comparison of fluconazole with amphotericin B as empiric antifungal agents in cancer patients with prolonged fever and neutropenia. Am. J. Med. (1998) 105:478–483.
   PubMed Web of Science ®Google Scholar
• ABBOTT M, HUGHES DL, PATEL R, KINGHORN GR: Angio-oedema after fluconazole. Lancet (1991) 338: 633.
   PubMed Web of Science ®Google Scholar
• AGARWAL A, SAKHAJA V, CHUGH KS: Fluconazole-induced thrombocytopenia. Ann. Intern. Med. (1990) 113:899.
   PubMed Web of Science ®Google Scholar
• PAPPAS PG, KAUFFMAN CA, PERFECT J, et al.: Alopeciaassociated with fluconazole therapy. Ann. Intern. Med. (1995) 123:354–357.
   PubMed Web of Science ®Google Scholar
• BOOGAERTS J, MICHAUX J-L, BOSLY A, et al.: Pharma-cokinetics and safety of seven days of intravenous (IV) itraconazole followed by two weeks oral itraconazole solution in patients with haematological malignancy. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, USA (1996) Abstract A–87.
   Google Scholar
• VANDEWOUDE K, VOGELAERS D, DECRUYENAERE J, et al.: Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrob. Agents Chemother. (1997)41:2714–2718.
   PubMed Web of Science ®Google Scholar
• ZHOU HH, GOLDMAN M, WU J, et al.: A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection. J. Clin. Pharmacol. (1998) 38:593-602. BAILEY EM, KRAKOVSKY DJ, RYBAK MJ: The triazole antifungal agents: a review of itraconazole and fluconazole. Pharmacotherapy (1990) 10:146-153. A concise review of commonly used current systemic triazoles. WILDFEUER A, SEIDL HP, PAULE I, HABERREITER A: In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and derrnatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses (1998) 41:309–319.
   Google Scholar
• BAILEY EM, KRAKOVSKY DJ, RYBAK MJ: The triazole antifungal agents: a review of itraconazole and fluconazole. Pharmacotherapy (1990) 10:146–153.
   PubMed Web of Science ®Google Scholar
• • A concise review of commonly used current systemic triazoles.
   Google Scholar
• WILDFEUER A, SEIDL HP, PAULE I, HABERREITER A: In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses (1998) 41:309–319.
   PubMed Web of Science ®Google Scholar
• UZUN O, ARIKAN S, KOCAGOZ S, SANCAK B, UNAL S: In vitro activity of voriconazole compared with flucona-zole, itraconazole and amphotericin B against Candida isolated in a Turkish University hospital. 21st International Congress of Chemotherapy. Birmingham, UK (1999) Abstract P47.
   Google Scholar
• NGUYEN MH, YU CY: Voriconazole against fluconazole-susceptible and resistant Candida isolates: in vitro efficacy compared with that of itraconazole and ketoconazole. J. Antimicrob. Chemother. (1998) 42:253–256.
   PubMed Web of Science ®Google Scholar
• MCGINNIS MR, PASARELL L, SUTTON DA, et al.: In vitro activity of voriconazole against selected fungi. Med. Mycol. (1998) 36:239–242.
   PubMed Web of Science ®Google Scholar
• MENICHETTI F, DEL FAVERO A, MARTINO P, et al.: Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. Clin. Infect. Dis. (1999) 28:250–255.
   PubMed Web of Science ®Google Scholar
• MICHALLET M, PERSAT F, KRANZHOFER N, et al.: Pharma-cokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation. Bone Marrow Transplant (1998) 21:1239–1243.
   PubMed Web of Science ®Google Scholar
• MEUNIER F: Future directions of antimycotic therapy.Mycoses (1994) 37:77–82.
   PubMed Web of Science ®Google Scholar
• DENNING DW, TUCKER RM, HANSON LH, STEVENS DA:Treatment of invasive aspergillosis with itraconazole. Am. J. Med. (1989) 86:791–800.
   PubMed Web of Science ®Google Scholar
• Speller DCE (Ed.), Wiley & Sons, Chichester, UK (1980)35–106.
   Google Scholar
• VAN DER HORST C, SAAG M, CLOUD G, et al.: Part 1. Randomized double blind comparison of amphotericin B plus flucytosine to amphotericin B alone (Step 1) Followed by a comparison of flucona-zole to itraconazole (Step 2) in the treatment of acute Cryptococcal meningitis in patients with AIDS. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1995) Abstract 1216.
   Google Scholar
• SAAG M, VAN DER HORST C, CLOUD G, et al.: Part 2. Randomized double blind comparison of amphotericin B plus flucytosine to amphotericin B alone (Step 1) Followed by a comparison of flucona-zole to itraconazole (Step 2) in the treatment of acute Cryptococcal meningitis in patients with AIDS. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1995) Abstract 1217.
   Google Scholar
• WHELAN WL: The genetic basis of resistance to 5-fluorocytosine in Candida species and Crypto-coccus neoformans. Grit. Rev. Microbiol . (1987) 15:45–56.
   PubMed Web of Science ®Google Scholar
• MAYANJA-KIZZA H, OISHI K, MITARAIS et al.: Combina-tion therapy with fluconazole and flucytosine for Cryptococcal meningitis in Ugandan patients with AIDS. Clin. Infect. Dis. (1998) 26:1362–1366.
   PubMed Web of Science ®Google Scholar
• DIAMOND DM, BAUER M, DANIEL BE, et al.: Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine Cryptococcal meningitis. Antimicrob. Agents Chemother. (1998) 42:528–533.
   PubMed Web of Science ®Google Scholar
• JUST-NOBLING G, HEISE W, RIEG G, et al.: Triple combination of amphotericin B, flucytosine and fluconazole for treatment of acute Cryptococcal meningitis in patients with AIDS. 3rd International Conference on Cryptococcus and Cryptococcosis. Paris, France (1996) Abstract V5.
   Google Scholar
• DENNING DW: Treatment of invasive aspergillosis. J. Infect. (1994) 28\(Suppl. 1):25–33.
   PubMed Web of Science ®Google Scholar
• YOON SA, VAZQUES JA, STEFFAN PE, SOBEL J, AKINS RA: High frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance. Antimi-crob. Agents Chemother. (1999) 43:836–845.
   PubMed Web of Science ®Google Scholar
• •Resistance of Candida lusitaniae to amphotericin B.
   Google Scholar
• BOKEN DJ, SWINDELLS S, RINALDI MG: Fluconazole-resistant Candida albicans. Clin. Infect. Dis. (1993) 17: 1018–1021.
   Google Scholar
• •Emergence of resistance to fluconazole in Candida albi cans strains.
   Google Scholar
• REX J, LOZANO-CHIU M, PAETZNICK V, et al.: Suscepti-bility testing of current Candida bloodstream isolates from Mycoses Study Group (MSG) collaborative study #34: Isolates of Candida krusei are often resistant to both fluconazole and amphotericin B. 36th Annual Meeting of the Infectious Diseases Society of America. Denver, USA (1998) Abstract 324.
   Google Scholar
• •Resistance of C. krusei to amphotericin B.
   Google Scholar
• YAMAMOTO Y, KLEIN TW, FRIEDMAN H, KIMURA S, YAMAGUCHI H: Granulocyte colony-stimulating factor potentiates anti-Candida albicans growth inhibitory activity of polymorphonuclear cells. FEMS Immunol. Med. Microbiol. (1993)7:15-22.
   Google Scholar
• ROILIDES E, HOLMES A, BLAKE C, et al.: Antifungal activity of elutriated human monocytes against Aspergillus fumigatus hyphae: enhancement by granulocyte-macrophage colony-stimulating factor and interferon-y. J. Infect. Dis. (1994) 170:894–899.
   PubMed Web of Science ®Google Scholar
• DENNING DW: Echinocandins and pneumocandins-a new antifungal class with a novel mode of action. J. Antimicrob. Chemother. (1997) 40:611–614.
   PubMed Web of Science ®Google Scholar
• ••A concise review article on echinocandins. GEORGOPAPADAKOU NH: Antifungals: mechanism of action and resistance, established and novel drugs. Curr. Opin. Microbiol. (1998) 1:547-557. Review article on currently available and emerging antifungal agents, focusing on resistance. DENNING DW: Invasive aspergillosis in irnmunocom-promised patients. Curr. Opin. Infect. Dis. (1994) 7:456–462.
   Web of Science ®Google Scholar
• GEORGOPAPADAKOU NH: Antifungals: mechanism of action and resistance, established and novel drugs. Curr. Opin. Microbiol. (1998) 1:547–557.
   PubMed Web of Science ®Google Scholar
• •• Review article on currently available and emerging antifungal agents, focusing on resistance.
   Google Scholar
• DENNING DW: Invasive aspergillosis in immunocompromised patients. Curr. Opin. Infect. Dis. (1994) 7:456–462.
   Web of Science ®Google Scholar
• BODEY GP: Infection in cancer patients: a continuing association. Am. J. Med. (1986) 81:11–26.
   PubMed Web of Science ®Google Scholar
• MEADE RH: Drug therapy reviews: clinical pharma-cology and therapeutic use of antimycotic drugs. Am.J. Hosp. Pharm. (1979) 36:1326–1334.
   PubMedGoogle Scholar
• MEHTA RT, HOPFER RL, GUNNER LA, JULIANO RL, LOPEZ-BERESTEIN G: Formulation, toxicity and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob. Agents Chemother. (1987) 31:1897–1900.
   PubMed Web of Science ®Google Scholar
• •Emergence of liposomal formulation of nystatin as a systemic antifungal agent.
   Google Scholar
• JESSUP CJ, WALLACE TJ, GHANNOUM MA: Evaluation of antifungal activity of Nyotran against various pathogenic fungi. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract F–88.
   Google Scholar
• WALLACE TL, PAETZNICK V, COSSUM PA, et al.: Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrob. Agents Chemother. (1997) 41:2238–2243.
   PubMed Web of Science ®Google Scholar
• ARIKAN S, LOZANO-CHIU M, PAETZNICK V, et al.: In vitro activity of liposomal nystatin compared with amphotericin B and fluconazole against clinical Candida isolates. 98th General Meeting of the American Society. for Microbiology. Atlanta, USA (1998) Abstract C–280.
   Google Scholar
• CARILLO-MUNOZ AJ, QUINDOS G, TUR C, et al.: In vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole. J. Antimicrob. Chemother. (1999) 44:397–401.
   PubMed Web of Science ®Google Scholar
• •Comparative in vitro activities of lipid formulations of nystatin and amphotericin B.
   Google Scholar
• MEHTA RT, HAYMAN A, SARIN P, LOPEZ-BERESTEIN G: AR-121. Drugs Future (1994) 19:724–730.
   Google Scholar
• MEHTA RT, HOPFER RL, MCQUEEN T, JULIANO RL, LOPEZ-BERESTEIN G. Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob. Agents Chemother. (1987) 31:1901–1903.
   PubMed Web of Science ®Google Scholar
• DENNING DW, WARN P: Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B. Antimicrob. Agents Chemother. (1999) 43:2592–2599.
   PubMed Web of Science ®Google Scholar
• ROLSTON K, BAIRD I, GRAHAM DR, JAUREGUI L: Treatment of refractory episodes of candidemia in non-neutropenic patients with liposomal nystatin (Nyotran). 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (1998) Abstract LB–1.
   Google Scholar
• RIOS A, ROSENBLUM M, CROFOOT G, et al.: Pharmacoki-netics of liposomal nystatin in patients with human immunodeficiency virus infection. J. Infect. Dis. (1993) 168:253–254.
   PubMed Web of Science ®Google Scholar
• POWLES R, MAWHORTER S, WILLIAMS T: Liposomal nystatin (Nyotran) vs. amphotericin B (Fungizone) in empiric treatment of presumed fungal infection in neutropenic patients. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1999) Abstract LB–4.
   Google Scholar
• •Clinical trial on empiric use of liposomal nystatin in febrile neutropenic patients.
   Google Scholar
• WILLIAMS AH, MOORE JE: Multicenter study to evaluate the safety and efficacy of various doses of liposome-encapsulated nystatin in non-neutropenic patients with candidemia. 39th Interscience Conference on Antimi-crobial Agents and Chemotherapy. San Francisco, USA (1999) Abstract J–1420.
   Google Scholar
• Scolnick E (Ed.), (2000). (In Press).
   Google Scholar
• COPLEY-MERRIMAN CR, RANSBURG NJ, CRANE LR, et al.: Cilofungin treatment of Candida esophagitis: prelimi-nary Phase II results. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, USA (1990) Abstract 581.
   Google Scholar
• COPLEY-MERRIMAN CR, GALLIS H, GRAYBILL JR, DOEBBELING BN, HYSLOP DL Cilofungin treatment of disseminated candidiasis: preliminary Phase II results. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, USA (1990) Abstract 582.
   Google Scholar
• KURTZ MB, HEATH IB, MARRINAN J, et al.: Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-p-o-g1ucan synthase. Antimicrob. Agents Chemother. (1994) 38:1480–1489.
   PubMed Web of Science ®Google Scholar
• •First evidence of distinctive inhibitory effect of echino-candins on A.spergillus isolates.
   Google Scholar
• ARIKAN S, LOZANO-CHIU M, PAETZNICK V, REX JH: In vitro susceptibility testing methods for caspofungin (CAS) against Aspergillus (ASP) and Fusarium (FUS) isolates. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1999) Abstract J–160.
   Google Scholar
• DE LUCCA AJ, WALSH TJ: Antifungal peptides: novel therapeutic compounds against emerging pathogens. Antimicrob. Agents Chemother. (1999) 43:1–11.
   PubMed Web of Science ®Google Scholar
• ••An extensive review article on antifungal peptides.
   Google Scholar
• MEULBROEK J, OLEKSIJEW A, TOVCIMAK A, et al.: Efficacy of A-175800.0, an inhibitor of fungal cell wall synthesis, against experimental systemic candidiasis. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract F–82.
   Google Scholar
• IWAMOTO T, FUJIE A, NITTA K, et al.: WF11899A, B and C, novel antifungal lipopeptides. II. Biological proper-ties. J. Antibiotics (1994) 47:1092–1097.
   PubMed Web of Science ®Google Scholar
• IWAMOTO T, FUJIE A, SAKAMOTO K, et al.: WF11899A, B and C, novel antifungal lipopeptides. I. Taxonomy, fermentation, isolation and physico-chemical proper-ties. J. Antibiotics (1994) 47:1084–1091.
   PubMed Web of Science ®Google Scholar
• HAWSER S, BORGONOVI M, MARKUS A, ISERT D: Mulundoncandins, an echinocandin-like lipopeptide antifungal agent: biological activities in vitro. J. Antibi-otics (1999) 52:305–310.
   PubMed Web of Science ®Google Scholar
• DOMINGUEZ JM, KELLY VA, KINSMAN OS, et al.: Sordarins: a new class of antifungals with selective inhibition of the protein synthesis elongation cycle in yeasts. Antimicrob. Agents Chemother. (1998) 42:2274–2278.
   PubMed Web of Science ®Google Scholar
• DOMINGUEZ JM, CAPA L, SERRAMIA MJ, et al.: Transla-tion elongation factor 2 (EF2) is the target for sordarin-derived antifungals. 37th Interscience Confer-ence on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract F–55.
   Google Scholar
• HERREROS E, MARTINEZ A, JIMENEZ E, et al.: Anti-pneumocystosis activity of GM 237354 in vitro and in vivo. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract F–64.
   Google Scholar
• BUENO JM, CHICHARRO J, HUSS SI, FIANDOR JM, GOMEZ DES LAS HERAS F: Synthesis of the antifungal GM 237354. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract F–54.
   Google Scholar
• HERREROS E, MARTINEZ CM, ALMELA MJ, et al Sordarins: In vitro activities of new antifungal deriva-tives against pathogenic yeasts, Pneumocystis carinii 136. and filamentous fungi. Antimicrob. Agents Chemother. (1998) 42:2863–2869.
   PubMed Web of Science ®Google Scholar
• AVILES P, PATEMAN A, SAN ROMAN R, GARGALLO D: Single-dose pharmacokinetic studies in rodents with GM237354, a new systemic antifungal agent. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract F–66.
   Google Scholar
• SANCHEZ-SOUSA A, ALVAREZ ME A, PARRA C, BAQUERO F: Activity on clinical yeast isolates of a new antifungal agent, GM 237354. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract F–56.
   Google Scholar
• HERREROS E, MARTINEZ CM, ALMELA MJ, et al.: In vitro activity of GM 237354 against a broad range of fungi. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract F–57.
   Google Scholar
• STEVENS DA: Screening of sordaricin derivatives against endemic fungal pathogens. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract F–58.
   Google Scholar
• ALIOUAT EM, AVILES P, DEI-CAS E, et al.: In vitro pharma-codynamic parameters of sordarin derivatives in comparison with marketed compounds against rat-derived Pneumocystis carinii. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (1998) Abstract J–15.
   Google Scholar
• ALVAREZ ME, HERREROS E, SANCHEZ-SOUSA A, GARGALLO-VIOLA D, BAQUERO F: In vitro activity of sordarins in combination with other systemic antifungal agents against Candida albicans, Aspergillus spp. and Scedosporium apiospermum. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (1998) Abstract J–12.
   Google Scholar
• CAPA L, MENDOZA A, LAVANDERA JL, GOMEZ DE LAS HERAS F, GARCIA-BUSTOS JF: Translation elongation factor 2 is part of the target for a new family of antifun-gals. Antimicrob. Agents Chemother. (1998) 42:2694–2699.
   PubMed Web of Science ®Google Scholar
• MARTINEZ A, JIMINEZ E, AVILES P, et al.: Antifungal activity of sordarin derivatives against fluconazole-susceptible and -resistant Candida albicans. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1999) Abstract J–294.
   Google Scholar
• MARTINEZ A, FERRER S, JIMENEZ E, et al.: Antifungal activity of sordarin derivatives against non-lethal models of candidiasis in rats. 39th Interscience Confer-ence on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1999) Abstract J–1999.
   Google Scholar
• GRAYBILL JR, NAJVAR L, FOTHERGILL A, BOCANEGRA R, GOMEZ DE LAS HERAS F: Activities of sordarins in murine histoplasmosis. Antimicrob. Agents Chemother. (1999) 43:1716–1718.
   PubMed Web of Science ®Google Scholar
• AVILES P, ALIOUAT EM, MARTINEZ A, et al.: Pharmacoki-netic/pharmacodynarnic (PK/PD) study of sordarin derivatives against Pneumocystis carinii pneumonia. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (1998) Abstract J–56.
   Google Scholar
• GATEHOUSE DG, WILLIAMS TC, SULLIVAN AT, et al.: Sordarins: toxicological evaluation and safety pharmacology in rats and dogs. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (1998) Abstract J–75.
   Google Scholar
• ESPINEL-INGROFF A: In vitro activities of the new triazole voriconazole (UK-109,496) against opportun-istic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. (1998) 36: 198–202.
   Google Scholar
• CLANCY CJ, NGUYEN MH: In vitro efficacy and fungicidal activity of voriconazole againstAspergillus and Fusarium species. Eur. J. Clin. Microbiol. Infect. Dis. (1998) 17: 573–575.
   Google Scholar
• LOZANO-CHIU M, ARIKAN S, PAETZNICK VL, ANAISSIE EJ, REX JH: Optimizing voriconazole susceptibility testing of Candida: effects of incubation time, endpoint rule, species of Candida and level of flucona-zole susceptibility. J. Clin. Microbiol. (1999)37:2755–2759.
   PubMed Web of Science ®Google Scholar
• JOHNSON EM, SZEKELY A, WARNOCK DW: In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J. Antimi-crob. Chemother. (1998) 42:741–745.
   PubMed Web of Science ®Google Scholar
• TROKE PF, BRAMMER KW, HITCHCOCK CA, YONREN S, SARANTIS N: UK-109,496, a novel, wide spectrum triazole derivative for the treatment of fungal infections: activity in systemic candidiasis models and early clinical efficacy in oropharyngeal candidiasis. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1995) Abstract F–73.
   Google Scholar
• LAW D, MOORE CB, DENNING DW: Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob. Agents Chemother. (1997) 41:2310–2311.
   PubMed Web of Science ®Google Scholar
• GALGIANI JN, LEWIS ML: In vitro studies of activities of the antifungal triazoles SCH 56592 and itraconazole against Candida albicans, Cryptococcus neoformans and other pathogenic yeasts. Antimicrob. Agents Chemother. (1997) 41:180–183.
   PubMed Web of Science ®Google Scholar
• OAKLEY KL, MOORE CB, DENNING DW: In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob. Agents Chemother. (1997) 41:1124–1126.
   PubMed Web of Science ®Google Scholar
• MARCO F, PFALLER MA, MESSER SA, JONES RN: In vitro activity of a new triazole antifungal agent, SCH 56592, against clinical isolates of filamentous fungi. Mycopa-thologia (1998) 141:73–77.
   PubMed Web of Science ®Google Scholar
• ESPINEL-INGROFF A: Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportun-istic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. (1998) 36: 2950–2956.
   Google Scholar
• FOTHERGILL AW, SUTTON DA, RINALDI MG: In vitro head-to-head comparison of Schering 56592, amphotericin B, fluconazole and itraconazole against a spectrum of filamentous fungi. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, USA (1996) Abstract F–89.
   Google Scholar
• SANCHE SE, FOTHERGILL AW, RINALDI MG: Interspecies variation of the susceptibility of Fusarium species to Schering 56592 in vitro. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract E–66.
   Google Scholar
• LOZANO-CHIU M, ARIKAN S, PAETZNICK VL, et al.: Treatment of murine fusariosis with SCH 56592. Antimicrob. Agents Chemother. (1999) 43:589–591.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MESSER S, JONES RN: Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccbaromyces cerevisiae. Antimi-crob. Agents Chemother. (1997) 41:233–235.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MESSER SA, HOLLIS RJ, et al.: In vitro suscep-tibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, SCH 56592 and voriconazole. Antimicrob. Agents Chemother. (1998) 42:3242–3244.
   PubMed Web of Science ®Google Scholar
• MUNAYYER H, SHAW KJ, HARE RS, et al.: SCH 56592 is a potent inhibitor of sterol C14 demethylation in fungi. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, USA (1996) Abstract F–92.
   Google Scholar
• FUNG-TOMC JC, HUCZKO E, MINASSIAN B, BONNER DP: In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob. Agents Chemother. (1998) 42:313–318.
   PubMed Web of Science ®Google Scholar
• HATA K, KIMURA J, MIKI H, et al.: In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob. Agents Chemother. (1996) 40:2237–2242.
   PubMed Web of Science ®Google Scholar
• HATA K, UNEO J, MIKI H, et al.: ER-30346, a novel antifungal triazole: Bl. In vitro activity and its mode of action. 35th Interscience Conference on antimicrobial Agents and Chemotherapy. San Francisco, USA (1995) Abstract F–92.
   Google Scholar
• PATTERSON BE, COATES PE: UK-109,496, a novel, wide spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1995):Abstract F–78.
   Google Scholar
• PATTERSON BE, ROFFEY S, JEZEQUEL SG, JONES B: UK-109,496, a novel, wide spectrum triazole derivative for the treatment of fungal infections: disposition in man. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1995):Abstract F–79.
   Google Scholar
• DENNING D, DEL FAVERO A, GLUCKMAN E, et al.: UK-109,496, a novel, wide spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in acute invasive aspergillosis. 35th Interscience Confer-ence on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1995):Abstract F–80.
   Google Scholar
• DUPONT B, DENNING D, LODE H, et al.: UK-109,496, a novel, wide spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in chronic invasive aspergillosis. 35th Interscience Confer-ence on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1995) Abstract F–81.
   Google Scholar
• SCHWARTZ S, MILATOVIC D, THIEL E: Successful treatment of cerebral aspergillosis with novel triazole (voriconazole) in a patient with acute leukemia. Br. J. Haematol. (1997) 97:663–665.
   PubMed Web of Science ®Google Scholar
• JABADO N, CASANOVA JL, HADDAD E, et al.: Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulo-matous disease. Clin. Infect. Dis. (1998) 27: 1437–1441.
   Google Scholar
• HEITMANN L, COMETTA A, HURNI M, et al.: Right-sided pacemaker-related endocarditis due to Acremonium species. Clin. Infect. Dis. (1997) 25:158–160.
   PubMed Web of Science ®Google Scholar
• RADWANSKI E, KOSOGLOU T, LIM et al.: 5CH56592: bioavailability of an oral suspension relative to a solid dosage form in healthy volunteers. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract A–86.
   Google Scholar
• NAKAMURA T, SAKAI R, SONODA J, et al.: ER-30346, a novel antifungal triazole: IV. Pharmacokinetics and toxicological studies in mice, rats and dogs. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1995) Abstract F–94.
   Google Scholar
• HATA K, KIMURA J, MIKI H, et al.: Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis and cryptococ-cosis. Antimicrob. Agents Chemother. (1996) 40:2243–2247.
   PubMed Web of Science ®Google Scholar
• LAUGHLIN M, PAT S, MENON S, et al.: SCH 56592: rising multiple-dose safety, tolerance and pharmacokinetic evaluation in healthy volunteers. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract A–87.
   Google Scholar
• UZUNO, KOCAGOZ S, CETINKAYA Y, ARIKAN S, UNAL S: In vitro activity of a new echinocandin, LT303366, compared with those of amphotericin B and flucona-zole against clinical yeast isolates. Antimicrob. Agents Chemother. (1997) 41:1156–1157.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MESSER SA, COFFMAN S: In vitro suscepti-bilities of clinical yeast isolates to a new echinocandin derivate, LY303366 and other antifungal agents. Antimicrob. Agents Chemother. (1997) 41:763–766.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MARCO F, MESSER SA, JONES RN: In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rbizopus and other filamen-tous fungi. Diagn. Microbiol. Infect. Dis. (1998)30:251–255.
   PubMed Web of Science ®Google Scholar
• OAKLEY KL, MOORE CB, DENNING DW: In vitro activity of the echinocandin antifungal agent LY303366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob. Agents Chemother. (1998) 42:2726–2730.
   PubMed Web of Science ®Google Scholar
• VAZQUEZ JA, LYNCH M, BOIKOV D, SOBEL JD: In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob. Agents Chemother. (1997) 41:1612–1614.
   PubMed Web of Science ®Google Scholar
• MARCO F, PFALLER MA, MESSER SA, JONES RN: Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn. Microbiol. Infect. Dis. (1998) 32:33–37.
   PubMed Web of Science ®Google Scholar
• BARTIZAL K, GILL CJ, ABRUZZO GK, et al.: In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. (1997) 41:2326–2332.
   PubMed Web of Science ®Google Scholar
• FRANZOT SP, CASADEVALL A: Pneumocandin L-743,872 enhances the activities of amphotericin B and flucona-zole against Cryptococcus neoformans in vitro. Antimicrob. Agents Chemother. (1997) 41:331–336.
   PubMed Web of Science ®Google Scholar
• FOTHERGILL AW, SUTTON DA, RINALDI MG: Antifungal susceptibility testing of Merck L-743,872 against a broad range of fungi. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, USA (1996):Abstract F–29.
   Google Scholar
• DEL POETA M, SCHELL WA, PERFECT JR: In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob. Agents Chemother. (1997) 41:1835–1836.
   PubMed Web of Science ®Google Scholar
• MAKI K, MORISHITA Y, IGUCHI Y et al.: In vitro antifungal activity of FK 463, a novel water-soluble echinocandin-like peptide. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (1998):Abstract F–141.
   Google Scholar
• NAKAI T, UNO J, MYAJI M: In vitro activity of FK463, a novel antifungal lipopeptide, against clinically important, less common molds and dimorphic fungi. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1999):Abstract J–1509.
   Google Scholar
• LUCAS R, DESANTE K, HATCHER B, et al.: LY303366 single dose pharmacokinetics and safety in healthy male volunteers. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, USA (1996):Abstract F–50.
   Google Scholar
• RAJMAN I, DESANTE K, HATCHER B, et al.: LY303366 single intravenous dose pharmacokinetics and safety in healthy volunteers. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract F–74.
   Google Scholar
• NI L, SMITH B, HATCHER B, et al.: Pharmacokinetics of LY303366 in healthy and HIV-infected volunteers after single-dose oral administration. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (1998):Abstract J–134.
   Google Scholar
• PETRAITIS V, PETRAITIENE R, CANDELARIO M, et al.: Efficacy of LY303366, a semisynthetic echinocandin, against fluconazole-resistant esophageal candidiasis. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (1998):Abstract J–72.
   Google Scholar
• PETRAITIENE R, PETRAITIS V, GROLL A, et al.: Efficacy of LY303366, a novel echinocandin, against dissemi-nated candidiasis in persistently neutropenic rabbits. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (1998):Abstract J–73.
   Google Scholar
• PETRAITIS V, PETRAITIENE R, GROLL AH, et al.: Antifungal efficacy, safety and single-dose pharma-cokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. (1998) 42:2898–2905.
   PubMed Web of Science ®Google Scholar
• VERWEIJ PE, OAKLEY KL, MORRISSEY J, MORRISSEY G, DENNING DW: Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob. Agents Chemother. (1998) 42:873–878.
   PubMed Web of Science ®Google Scholar
• STONE JA, HOLLAND SD, JU WD, et al.: Single- and multiple-dose pharmacokinetics of the antifungal agent MK-0991 in man. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (1998):Abstract C–51.
   Google Scholar
• SABLE CA, VILLANUEVA A, ARATHON E, et al.: A random-ized, double-blind, multicenter trial of MK-991 (L-743,872) vs. amphotericin B in the treatment of Candida esophagitis in adults. 37th Interscience Confer-ence on Antimicrobial Agents and Chemotherapy. Toronto, Canada (1997) Abstract LB–33.
   Google Scholar
• POWLES MA, LIBERATOR P, ANDERSON J, et al.: Efficacy of MK-991 (L-743,872), a semisynthetic pneumo-candin, in murine models of Pneumocystis Antimicrob. Agents Chemother. (1998) 42:1985–1989.
   PubMed Web of Science ®Google Scholar
• AZUMA J, YAMAMOTO I, OGURA M, et al.: Phase I study of FK463, a new antifungal agent, in healthy adult male volunteers. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, USA (1998) Abstract F–146.
   Google Scholar
• PETTENGELL K, MYNHARDT J, KLUYTS S, SONI P: A multicenter study to determine the minimal effective dose of FK463 for the treatment of esophageal candidiasis in HIV-positive patients. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1999) Abstract J–1421.
   Google Scholar
• HIEMENZ J, CAGNONI P, SIMPSON D, DEVINE S, CHAO N: Maximum tolerated dose and pharmacokinetics of FK463 in combination with fluconazole for the prophylaxis of fungal infections in adult bone marrow or peripheral stem cell transplant patients. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1999) Abstract J–1648.
   Google Scholar
• SELSTED M, SZKLAREK D, GANZ T, LEHRER R: Activity of rabbit leukocyte peptides against Candida albicans. Infect. Immun. (1985) 49:202–206.
   PubMed Web of Science ®Google Scholar
• ALCOULOUMBRE MS, GHARINOUM MA, IBRAHIM AS, SELSTED ME, EDWARDS JE: Fungicidal properties of defensin NP-1 and activity against Cryptococcus neoformans in vitro. Antimicrob. Agents Chemother. (1993) 37:2628–2632.
   PubMed Web of Science ®Google Scholar
• SEGAL GP, LEHRER RI, SELSTED ME: In vitro effect of phagocyte cationic peptides on Coccidioides immitis. J. Infect. Dis. (1985) 151:890–894.
   Google Scholar
• LEVITZ SM, SELSTED ME, GANZ T, LEHRER RI, DIAMOND RD: In vitro killing of spores and hyphae of Aspergillus fumigatus andRbizopus oryzae by rabbit neutrophil cationic peptides and bronchoalveolar macrophages. J. Infect. Dis. (1986) 154:483–489.
   PubMed Web of Science ®Google Scholar
• LEHRER RI, GANZ T, SZKLAREK D, SELSTED ME: Modula-tion of the in situ candidacidal activity of human neutrophil defensins by target cell metabolism and divalent cations. J. Clin. Invest. (1988) 81:1829–1835.
   PubMed Web of Science ®Google Scholar
• GANZ T, SELSTED ME, SZKLAREK D, et al.: Natural peptide antibiotics of human neutrophils. J. Clin. Invest. (1985) 76:1427–1435.
   PubMed Web of Science ®Google Scholar
• LAWYER CS, PALS, WATEBE M, et al.: Effects of synthetic form of tracheal antimicrobial peptide on respiratory pathogens. J. Antimicrob. Chemother. (1996) 37:599–604.
   PubMed Web of Science ®Google Scholar
• YAMAUCHI K, TOMITA M, GIEHL TJ, ELLISON RT: Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect. Immun. (1993) 61:719–728.
   PubMed Web of Science ®Google Scholar
• HECTOR RF, ZIMMER BL, PAPPAGIANIS D: Evaluation of nikkomycins X and Z in murine models of cocidioido-mycosis, histoplasmosis, blastomycosis. Antimicrob. Agents Chemother. (1990) 34:587–593.
   PubMed Web of Science ®Google Scholar
• BECKER JM, COVERT NL, SHENBAGAMURTHI P, STEINFELD AS, NAIDER F: Polyoxin D inhibits growth of zoopathogenic fungi. Antimicrob. Agents Chemother. (1983) 23:926–929.
   PubMed Web of Science ®Google Scholar
• GOTTLIEB S, ALTBOUM Z, SAVAGE DC, SEGAL E: Adhesion of Candida albicans to epithelial cells: effect of polyoxin D. Mycopathology (1991)115:197-216.
   Google Scholar
• IWAMOTO T, FUJIIE A, TSURUMI Y, NANBATA K, SHIBUYA K: FR900403, a new antifungal produced by a Kernia spp. J. Antibiotics (1990) 43: 1183–1185.
   Google Scholar